Unlocking the Potential: Antihistamine Use and Breast Cancer Risk in Women With Type 2 Diabetes Mellitus
Search for other papers by Kang-Chuang Chai in
Current site
Google Scholar
PubMed
Department of General Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
College of Medicine, Taipei Medical University, Taipei, Taiwan
Division of Transplantation Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
TMU Research Center for Organ Transplantation, Taipei Medical University, College of Medicine, Taipei, Taiwan
Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
Search for other papers by Ta-Chun Chou in
Current site
Google Scholar
PubMed
Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan
Search for other papers by Wan-Ming Chen in
Current site
Google Scholar
PubMed
Artificial Intelligence Development Center, Fu Jen Catholic University, Taipei, Taiwan
Search for other papers by Ben-Chang Shia in
Current site
Google Scholar
PubMed
College of Medicine, Taipei Medical University, Taipei, Taiwan
Division of Transplantation Surgery, Department of Surgery, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
TMU Research Center for Organ Transplantation, Taipei Medical University, College of Medicine, Taipei, Taiwan
Taipei Cancer Center, Taipei Medical University, Taipei, Taiwan
Search for other papers by Ruey-Shyang Soong in
Current site
Google Scholar
PubMed
Big Data Center, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
Division of Radiation Oncology, Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, Yilan, Taiwan
Department of Healthcare Administration, College of Medical and Health Science, Asia University, Taichung, Taiwan
Centers for Regional Anesthesia and Pain Medicine, Wan Fang Hospital, Taipei Medical University, Taipei, Taiwan
Search for other papers by Szu-Yuan Wu in
Current site
Google Scholar
PubMed
Background: The association between the use of antihistamines targeting histamine receptor H1 (AH1) and breast cancer risk in individuals with type 2 diabetes mellitus (T2DM) remains understudied, warranting further investigation. Methods: Using the Taiwan National Health Insurance Research Database from 2008 to 2018, we conducted a cohort study on women aged ≥18 years with T2DM, employing propensity score matching (PSM) to compare breast cancer risk between AH1 users (defined as at least 28 cumulative defined daily doses annually) and nonusers. Cox regression models were used to estimate adjusted hazard ratios (aHRs). Results: The baseline characteristics of the study population were assessed, with 142,642 women enrolled between 2008 and 2018. After PSM, the AH1 use and nonuse groups showed comparable variables. The aHR for breast cancer was significantly lower in the AH1 use group compared with the nonuse group (aHR, 0.54; 95% CI, 0.44–0.66; P<.0001). Dose-dependent analysis revealed a significant trend (Ptrend=.0002), indicating a lower breast cancer risk with increasing AH1 use. The incidence rate of breast cancer was lower in AH1 users compared with nonusers, with an incidence rate ratio of 0.78 (95% CI, 0.65–0.93). Conclusions: AH1 use shows promise in reducing breast cancer risk in individuals with T2DM, particularly with higher dosages, warranting further research and consideration by health care practitioners.
Submitted June 2, 2023; final revision received September 4, 2024; accepted for publication October 3, 2024.
K.C. Chai and T.C. Chou contributed equally to this study as joint primary authors.
R.S. Soong and S.Y. Wu are co–last authors.
Author contributions: Concept & design: All authors. Collection & assembly of data: Chai, Chou. Data analysis & interpretation: Chai, Chou, Soong. Administrative support: Wu. Manuscript writing: Chai, Chou, Soong, Wu.
Funding: This work was supported by the Lo-Hsu Medical Foundation, Lotung Poh-Ai Hospital, which supported the work of Prof. Szu-Yuan Wu (funding numbers: 11403 and 11404).
Data availability statement: The data sets supporting the study conclusions are included in the manuscript. We used data from the National Health Insurance Research Database and Taiwan Cancer Registry database. The authors confirm that, for approved reasons, some access restrictions apply to the data underlying the findings. The data used in this study cannot be made available in the manuscript, the supplemental files, or in a public repository due to the Personal Information Protection Act executed by Taiwan’s government, starting in 2012. Requests for data can be sent as a formal proposal to obtain approval from the ethics review committee of the appropriate governmental department in Taiwan. Specifically, links regarding contact info for which data requests may be sent to are as follows: http://nhird.nhri.org.tw/en/Data_Subsets.html#S3 and http://nhis.nhri.org.tw/point.html.
Supplementary material: Supplementary material associated with this article is available online at https://doi.org/10.6004/jnccn.2024.7077. The supplementary material has been supplied by the author(s) and appears in its originally submitted form. It has not been edited or vetted by JNCCN. All contents and opinions are solely those of the author. Any comments or questions related to the supplementary materials should be directed to the corresponding author.
Supplementary Materials
- Supplemental Materials (PDF 747 KB)
© 2019-2024 National Comprehensive Cancer Network